Mesoblast Enters into Non-Dilutive Lower Cost 5-Year Credit
Filed with ASX · · 2 pages · English
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings CallStory so far
Earlier from Mesoblast
- Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line
- Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD
- Mesoblast Participation at Piper Sandler Conference
- Ryoncil Revenue Growth Highlighted in AGM Trading Update
- CEO Presentation to 2025 Annual General Meeting
Later from Mesoblast
- Mesoblast Announces Changes to Board of Directors' Leadership Roles
- Ryoncil® Sales Increase 60% in December Quarter to US$35.1M
- Ryoncil Sales for the Quarter Increase 60% to US$35.1M
- FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy
- Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast